However, of the 24 DLBCL patients with ≥ 20% FOXP2 expression, only 5 exhibited < 70% FOXP1 expression and a significant enrichment of FOXP2-positive DLBCL (≥ 20% FOXP2 positivity) within the FOXP1-positive category (≥ 70% FOXP1) was observed (P = 0.0187; Table 3). This evidence concerns the gene FOXP2 and diffuse large B-cell lymphoma.